Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552220 | 0.86 | KMT2A (0.56) | PKMRAD52KDM4ERAB9AL3MBTL1 | |
| SCHEMBL8492272 | 0.84 | APP (0.54) | L3MBTL1ALDH1A1SMN1; SMN2IGF1RFGFR1 | |
| SCHEMBL3555953 | 0.82 | ALDH1A1 (0.52) | PTGDRKDM4ECCNT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3551906 | 0.81 | PKM (0.53) | PKMRAD52KDM4ENPC1RAB9A | |
| SCHEMBL21593125 | 0.81 | CYP1A2 (0.51) | PTGDRKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL1312011 | 0.80 | PKM (0.66) | PKMRAD52KDM4ENPC1RAB9A | |
| SCHEMBL3036480 | 0.78 | PIK3CA (0.67) | PKMRAD52ALDH1A1MKNK1MKNK2 | |
| SCHEMBL13406356 | 0.78 | PIK3CA (0.57) | RAD52PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL994275 | 0.74 | CDC7 (0.72) | MKNK2FGFR1KDR | |
| SCHEMBL13406330 | 0.73 | CYP1A2 (0.60) | PKMKDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| WO-2007042810-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | PTGDR 734/4885PKM 502/4885RAD52 3444/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PTGDR 1216/4885PKM 3764/4885RAD52 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.